tert-Butyl--keton | 81128-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: tert-Butyl--keton
• 英文别名: 2,2-dimethyl-1-quinolin-4-yl-propan-1-one；2,2-Dimethyl-1-quinolin-4-ylpropan-1-one
• CAS: 81128-32-7
• 化学式: C₁₄H₁₅NO
• 分子量: 213.279
• InChiKey: PQUPOCXHFXVCNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲基乙酰氯 、 4-trimethylstannyl-quinoline 在 palladium dichloride 作用下， 以 苯 为溶剂， 反应 96.0h， 以7%的产率得到tert-Butyl--keton
  参考文献：
  名称：

  Yamamoto, Yutaka; Yanagi, Akihiko, Chemical and pharmaceutical bulletin, 1982, vol. 30, # 6, p. 2003 - 2010

  摘要：

  DOI：

文献信息

• L-ALANINE DERIVATIVES
  申请人：Kettle Grant Jason

  公开号：US20090111828A1

  公开（公告）日：2009-04-30

  The present invention relates to compounds that inhibit of a5 b 1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5 b 1 and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有其作为活性成分的制药组合物，以及它们作为药物的使用和用于制造药物以治疗温血动物（如人类）中具有显著血管生成或血管成分的疾病，如固体肿瘤的治疗。本发明还涉及抑制a5b1并且对其他整合素具有适当选择性特征的化合物。
• L-Phenylalanine Derivatives
  申请人：Barry Simon Thomas

  公开号：US20090137601A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，以及包含其作为活性成分的制药组合物，以及它们作为药物在温血动物（如人类）中治疗具有显著血管生成或血管成分的疾病，如实体肿瘤的制剂中的用途。本发明还涉及抑制a5b1的化合物，以及对其他整合素具有适当选择性谱的化合物。
• CHEMICAL COMPOUNDS
  申请人：Arnould Jean Claude

  公开号：US20090203663A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有它们作为活性成分的制药组合物，它们作为药物的使用以及它们在制造用于治疗具有显著血管生成或血管成分的疾病的药物中的使用，如用于治疗实体肿瘤等温血动物（如人类）。本发明还涉及抑制a5b1的化合物，以及对其他整合素具有适当选择性特征的化合物。
• YAMAMOTO, YUTAKA;YANAGI, AKIHIKO, CHEM. AND PHARM. BULL., 1982, 30, N 6, 2003-2010
  作者：YAMAMOTO, YUTAKA、YANAGI, AKIHIKO

  DOI：——

  日期：——
• [EN] L-PHENYLALANINE DERIVATIVES<br/>[FR] DERIVES DE L-PHENYLALANINE
  申请人：ASTRAZENECA AB

  公开号：WO2007060408A2

  公开（公告）日：2007-05-31

  [EN] The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.
  [FR] L'invention concerne des composés qui inhibent la fonction a5b1, des procédés de préparation de ceux-ci, des compositions pharmaceutiques les contenant en tant qu'ingrédient actif, leur utilisation en tant que médicaments et leur utilisation dans la fabrication de médicaments servant à traiter des animaux à sang chaud, par exemple des humains, qui souffrent de maladies dans lesquelles une composante vasculaire ou d'angiogenèse significative est présente, de type tumeurs solides. L'invention concerne également des composés qui inhibent la fonction a5b1, et qui présentent un ou des profils de sélectivité appropriés contre d'autres intégrines.